UNC School of Medicine researcher Sarah Cohen, PhD, and Ian Windham, a former PhD student from the Cohen lab, have made a new discovery about apolipoprotein E (APOE) – the biggest genetic risk factor for late-onset Alzheimer’s disease.
ConSynance wins FDA designation for Prader-Willi syndrome therapy – Pharmaceutical Technology
CSTI-500 works by increasing the levels of monoamine neurotransmitters in the synaptic cleft. Image credit: Shutterstock / nobeastsofierce. The US Food and Drug Administration (FDA)
July 25, 2024